SurpassMD review

Every published GLP-1 price is qualified as promotional

SurpassMD advertises semaglutide as low as $114 a month and tirzepatide as low as $177. Its FAQ qualifies those amounts as available to eligible patients with a promotion and says actual pricing depends on the medication, dose and provider approval. The ordinary nonpromotional price is not published. These figures should therefore be treated as conditional opening information, not guaranteed standing rates that can be multiplied across a year's care without further explanation.

The missing regular price matters even if the promotion applies to the first order. Ask how long it lasts, which product and dose qualify, what renews afterward and whether a minimum term is attached. A written quote should identify the supply period and all required charges as well as the discounted amount. Without those details, a patient cannot know whether an apparently affordable entry represents the continuing budget or merely a short stage of a more expensive plan. Clinical suitability should be resolved independently of promotion eligibility.

National access and cold shipping are separate service claims

SurpassMD claims licensing across fifty states and the District of Columbia and describes 503A compounding, tracked cold-chain shipping and dispatch within forty-eight hours. Those statements can help frame questions about fulfillment, but they should not be converted into a guaranteed delivery date or assurance that every prescription can be filled at every address. Provider review, dispensing and carrier transit are different stages. Ask what timing applies after approval and how a problem with a temperature-sensitive shipment is handled.

The service identifies Life Vitality LLC as its operating company. Its Lewes, Delaware address is a registered-agent address rather than evidence of a clinic that a patient can visit. Corporate disclosure is useful without establishing an in-person care option or naming the actual dispensing pharmacy. Request the responsible practice, prescriber and pharmacy identities, and determine where questions about the prescription go after delivery. A 503A description explains a compounding category, not FDA approval of the finished preparation or the experience of an individual clinician.

The oral option and projection graphic need their own context

SurpassMD lists oral semaglutide tablets without a public price. The injection promotion should not be transferred to that product, nor should the oral form be presumed equivalent to an approved branded tablet. Discuss the exact preparation and instructions with the clinician, then obtain a separate financial quote. The homepage's weight-loss slider and longer-term projection are expressly labeled illustrative by the company. They are marketing estimates rather than a personalized forecast, a measured patient average or a guarantee that justifies a larger purchase.

HSA and FSA payment and installment options are advertised, along with cancel-anytime language. Those features do not settle financing costs, refund rights or what happens once dispensing begins. Ask for the selected agreement and future-billing cutoff before relying on a convenient payment method. Women seeking postpartum or hormonal care should also establish the clinician's actual scope rather than infer specialization from national availability. SurpassMD is most useful to investigate when its access and fulfillment model fit, but the essential financial answer remains the complete postpromotion quote and understandable terms for continuing or ending treatment. An unpriced oral option cannot inherit either injection promotion merely because it appears beside them.